[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1257219A1 - 美登素類化合物衍生物、其偶聯物和使用方法 - Google Patents

美登素類化合物衍生物、其偶聯物和使用方法

Info

Publication number
HK1257219A1
HK1257219A1 HK18116222.6A HK18116222A HK1257219A1 HK 1257219 A1 HK1257219 A1 HK 1257219A1 HK 18116222 A HK18116222 A HK 18116222A HK 1257219 A1 HK1257219 A1 HK 1257219A1
Authority
HK
Hong Kong
Prior art keywords
conjugates
methods
maytansinoid derivatives
maytansinoid
derivatives
Prior art date
Application number
HK18116222.6A
Other languages
English (en)
Inventor
Thomas Nittoli
Thomas P Markotan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1257219A1 publication Critical patent/HK1257219A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK18116222.6A 2016-01-25 2018-12-18 美登素類化合物衍生物、其偶聯物和使用方法 HK1257219A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662286858P 2016-01-25 2016-01-25
PCT/US2017/014782 WO2017132173A1 (en) 2016-01-25 2017-01-24 Maytansinoid derivatives, conjugates thereof, and methods of use

Publications (1)

Publication Number Publication Date
HK1257219A1 true HK1257219A1 (zh) 2019-10-18

Family

ID=57995285

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116222.6A HK1257219A1 (zh) 2016-01-25 2018-12-18 美登素類化合物衍生物、其偶聯物和使用方法

Country Status (20)

Country Link
US (4) US9950076B2 (zh)
EP (1) EP3408271B1 (zh)
JP (1) JP6934010B2 (zh)
KR (1) KR20180099892A (zh)
CN (2) CN114478801A (zh)
AU (1) AU2017211120C1 (zh)
BR (1) BR112018014759B1 (zh)
CA (1) CA3011440A1 (zh)
CL (1) CL2018002012A1 (zh)
CO (1) CO2018008761A2 (zh)
EA (1) EA039072B9 (zh)
HK (1) HK1257219A1 (zh)
IL (1) IL260744B (zh)
MA (1) MA43094B1 (zh)
MX (1) MX2018008987A (zh)
MY (1) MY198605A (zh)
PH (1) PH12018501589A1 (zh)
SG (1) SG11201806322QA (zh)
WO (1) WO2017132173A1 (zh)
ZA (1) ZA201804593B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902872A1 (en) 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
ES2971045T3 (es) 2015-07-06 2024-06-03 Regeneron Pharma Moléculas multiespecíficas de unión a antígeno y usos de las mismas
KR20180099892A (ko) * 2016-01-25 2018-09-05 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
AU2018365946A1 (en) 2017-11-07 2020-05-14 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
MX2020011487A (es) 2018-04-30 2020-12-07 Regeneron Pharma Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
KR20210107752A (ko) 2018-12-21 2021-09-01 리제너론 파마슈티칼스 인코포레이티드 리파마이신 유사체 및 이의 항체-약물 접합체
CA3128519A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
JP2022547274A (ja) 2019-09-16 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
US20220387618A1 (en) 2019-11-15 2022-12-08 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2021174113A1 (en) 2020-02-28 2021-09-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind her2, and methods of use thereof
KR20230004651A (ko) 2020-04-16 2023-01-06 리제너론 파마슈티칼스 인코포레이티드 딜스-알더 접합 방법
EP4406608A3 (en) 2020-07-13 2024-10-30 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
EP4210767A1 (en) 2020-09-14 2023-07-19 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
CA3198294A1 (en) 2020-11-10 2022-05-19 Thomas Nittoli Selenium antibody conjugates
KR20240134010A (ko) 2022-01-12 2024-09-05 리제너론 파마슈티칼스 인코포레이티드 단백질의 글루타민 잔기에 접합된 캄프토테신 유사체 및 이의 용도
US20230330254A1 (en) 2022-03-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-tethered drug conjugates comprising glp1 peptidomimetics and uses thereof
US20240269308A1 (en) 2022-12-21 2024-08-15 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
CN116239607B (zh) * 2023-01-04 2024-04-09 山东大学 一种美登素衍生物及其生物合成方法与应用
CN117257977A (zh) * 2023-11-07 2023-12-22 正大天晴药业集团南京顺欣制药有限公司 用于制备抗体药物偶联物的方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) * 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
CA2855359A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, an n-mustard alkylating agent and prednisone for treatment and management of multiple myeloma
US7659241B2 (en) * 2002-07-31 2010-02-09 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101581040B1 (ko) 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CN1997402B (zh) * 2004-05-19 2014-04-02 梅达雷克斯有限责任公司 化学连接基团及其缀合物
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
DK2135881T3 (da) 2005-06-20 2011-12-05 Genentech Inc Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
DK2845866T3 (en) 2006-10-27 2017-07-10 Genentech Inc Antibodies and immunoconjugates and their applications
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP3269366B1 (en) 2008-03-18 2020-01-15 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and lapatinib, and methods of use
NZ588851A (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
TWI461428B (zh) * 2008-07-15 2014-11-21 Genentech Inc 蔥環黴素衍生結合物，其製備方法及作為抗腫瘤化合物之用途
US8969626B2 (en) 2008-07-21 2015-03-03 Polytherics Limited Reagents and method for conjugating biological molecules
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2889624B1 (en) 2009-08-10 2018-10-03 UCL Business PLC Reversible covalent linkage of functional molecules
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
IN2012DN02780A (zh) 2009-10-06 2015-09-18 Immunogen Inc
WO2011081928A2 (en) 2009-12-14 2011-07-07 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
RS52983B (en) 2010-04-15 2014-02-28 Spirogen Sárl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
WO2012028579A1 (de) 2010-09-01 2012-03-08 Bayer Cropscience Ag N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
CN106349254A (zh) * 2010-11-03 2017-01-25 伊缪诺金公司 包含新型安丝菌素衍生物的细胞毒性剂
CA2836338C (en) 2011-05-16 2022-05-03 Koninklijke Philips N.V. Tetrazine derivatives used in bio-orthogonal drug activation
SG195183A1 (en) 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
US9102704B2 (en) 2011-10-14 2015-08-11 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
EP2861261A2 (en) 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
HUE062385T2 (hu) * 2012-10-23 2023-10-28 Synaffix Bv Módosított antitest, antitest-konjugátum és eljárás ezek elõállítására
NO2789793T3 (zh) 2012-10-24 2018-01-27
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
CN104650113A (zh) * 2012-12-21 2015-05-27 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
EP2764866A1 (en) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
CA2902872A1 (en) * 2013-03-15 2014-09-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CN103254311B (zh) 2013-05-09 2015-05-13 齐鲁制药有限公司 一种制备抗体-美登素类生物碱药物偶联物的方法
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014197871A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-drug conjugates, compositions and methods of use
US11229711B2 (en) 2013-06-06 2022-01-25 Magenta Therapeutics, Inc. Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US10781259B2 (en) 2013-06-06 2020-09-22 Magenta Therapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
KR102320019B1 (ko) 2013-11-27 2021-11-01 레드우드 바이오사이언스 인코포레이티드 히드라지닐-피롤로 화합물 및 콘쥬게이트 제조 방법
EP3077402B1 (en) 2013-12-02 2018-09-19 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
WO2016160615A1 (en) 2015-03-27 2016-10-06 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
KR20180099892A (ko) 2016-01-25 2018-09-05 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
SG10202102617QA (en) 2016-09-23 2021-04-29 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Also Published As

Publication number Publication date
CN108779127A (zh) 2018-11-09
WO2017132173A1 (en) 2017-08-03
ZA201804593B (en) 2022-12-21
US20170209591A1 (en) 2017-07-27
MY198605A (en) 2023-09-08
CN108779127B (zh) 2022-07-05
EA201800444A1 (ru) 2019-04-30
AU2017211120C1 (en) 2021-10-07
US20180289834A1 (en) 2018-10-11
US9950076B2 (en) 2018-04-24
CL2018002012A1 (es) 2018-08-31
BR112018014759A2 (pt) 2018-12-11
IL260744B (en) 2021-03-25
US20200121806A1 (en) 2020-04-23
BR112018014759B1 (pt) 2024-02-27
MA43094A1 (fr) 2019-06-28
EP3408271B1 (en) 2023-01-11
CN114478801A (zh) 2022-05-13
US20230116771A1 (en) 2023-04-13
EA039072B9 (ru) 2022-02-04
US10463749B2 (en) 2019-11-05
CO2018008761A2 (es) 2018-10-22
KR20180099892A (ko) 2018-09-05
AU2017211120A1 (en) 2018-07-26
JP2019502746A (ja) 2019-01-31
CA3011440A1 (en) 2017-08-03
PH12018501589A1 (en) 2019-04-08
MA43094B1 (fr) 2020-10-28
MX2018008987A (es) 2018-11-19
AU2017211120B2 (en) 2021-04-01
EA039072B1 (ru) 2021-11-30
JP6934010B2 (ja) 2021-09-08
SG11201806322QA (en) 2018-08-30
EP3408271A1 (en) 2018-12-05
US11446389B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
HK1257219A1 (zh) 美登素類化合物衍生物、其偶聯物和使用方法
ZA201706040B (en) Maytansinoid derivatives, conjugates thereof, and methods of use
IL261428A (en) Antibody-drug conjugates based on eribulin and methods of use
IL261493A (en) Napi2b-targeted antibody conjugates - drug and methods of using them
IL248961A0 (en) Oristatin histories and their conjugations
HK1231367A1 (zh) 抗體藥物偶聯物、試劑和製備方法及其治療用途
EP3204018A4 (en) Neoadjuvant use of antibody-drug conjugates
EP3151830A4 (en) Anti-her2 antibody-maytansine conjugates and methods of use thereof
EP3138568A4 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
EP3154971A4 (en) Heterocyclic morphinan derivatives and use thereof
EP3386986A4 (en) OR-PEG PORPHYRIN CONJUGATES AND METHODS OF USE
IL275190A (en) Anti-CD22 antibody-maytensin conjugates, combinations and methods of using them
IL249394A0 (en) Anti-cd22 drug-antibody conjugates and methods of using them
EP3283493A4 (en) Texaphyrin-phospholipid conjugates and methods of preparing same
EP3560517A4 (en) APTAMER INGREDIENT CONJUGATE AND USE OF IT
IL263172A (en) The history of three-ring heterocycles, their preparation and use
HK1256368A1 (zh) 加利車黴素-抗體-藥物綴合物和使用方法
HK1258409A1 (zh) 抗cd22抗體-美登木素綴合物及其使用方法
IL261643B (en) Piperidine derivatives, their preparation and use
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
PL3166945T3 (pl) Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie
EP3703745A4 (en) IMMUNOGENIC CONJUGATES AND METHOD OF USING THEREOF
EP3426352A4 (en) CAMPTOTHECIN DERIVATIVES AND USES THEREOF
ZA201904654B (en) Benzimidazole derivatives, preparation methods and uses thereof